ArteraAI has announced the validation of its AI-based digital pathology biomarker for predicting metastasis risk in prostate cancer patients who have undergone radical prostatectomy and subsequently experienced biochemical recurrence (BCR). This biomarker will help clinicians determine the optimal treatment plan for these patients.

After a radical prostatectomy, about 20-40% of patients develop BCR, indicating a risk of cancer spread. Salve radiotherapy is typically recommended, and clinicians may also consider adding hormone therapy.

Researchers developed the biomarker using multimodal deep learning on digital histopathology data from over 1,800 radical prostatectomy patients. The model successfully estimated metastasis risk and identified patients who would benefit significantly from hormone therapy and salvage radiotherapy.

Dr. Todd Morgan indicated that this biomarker will empower clinicians and patients to better understand disease progression risk and guide treatment decisions.

This biomarker represents a significant advancement as the first AI-based model developed specifically for radical prostatectomy patients with BCR. It demonstrated prognostic capabilities and the ability to predict differential benefits of hormone therapy addition.

Andre Esteva, Co-founder and CEO of ArteraAI, indicated that their digital pathology platform is expanding to support patients who have undergone radical prostatectomy.

Source link:

author avatar
Ferry Darma
Ferry Darma is Director of Media Relations at The Clinical Trial Vanguard. Ferry, a computer data scientist, focuses on the latest clinical trial industry news and trends.